Advanced search
Publication Cover
Acta Cardiologica Volume 78, 2023 - Issue 8
Submit an article Journal homepage
505
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Special issue on ischaemic heart disease

Patrizio LancellottiDepartment of Cardiology, CHU SartTilman, University of Liège Hospital, GIGA Cardiovascular Sciences, Liège, BelgiumCorrespondence[email protected]
Pages 859-862 | Published online: 28 Sep 2023

References

  • Claeys MJ. Reperfusion injury in STEMI patients: another piece of the puzzle. Acta Cardiol. 2023;78(1):162–163. doi: 10.1080/00015385.2022.2027636.
  • Lancellotti P, Cosyns B. Highlights of acta cardiologica. Acta Cardiol. 2022;77(6):469–470. doi: 10.1080/00015385.2022.2143092.
  • Lancellotti P, Petitjean H, Nchimi A, et al. Special issue on ischemic heart disease. Acta Cardiol. 2023;78(1):1–4. doi: 10.1080/00015385.2023.2170563.
  • Dahiya N, Kaur M, Singh V. Potential roles of circulatory microRNAs in the onset and progression of renal and cardiac diseases: a focussed review for clinicians. Acta Cardiol. 2023;78(8):863–877. doi: 10.1080/00015385.2023.2221150.
  • Coban N, Erkan AF, Ozuynuk-Ertugrul AS, et al. Investigation of miR-26a-5p and miR-19a-3p expression levels in angiographically confirmed coronary artery disease. Acta Cardiol. 2023;78(8):945–956. doi: 10.1080/00015385.2023.2227484.
  • Velibey Y, Yuksel G, Renda E, et al. Myocardial bridge in multiple coronary arteries. Acta Cardiol. 2022;77(1):93–94. doi: 10.1080/00015385.2020.1867779.
  • Narayanan S, Joseph S, Varghese AC, et al. Plaque morphology and distribution in patients with and without myocardial bridge – an intravascular ultrasound study. Acta Cardiol. 2023;78(8):894–900. doi: 10.1080/00015385.2023.2187117.
  • Sánchez ME, Makhoul SS, Villa-Etchegoyen C. Evaluation of coronary arteries and bicuspid aortic valve by three-dimensional transesophageal echocardiography. Acta Cardiol. 2023;78(8):964–965. doi: 10.1080/00015385.2023.2240117.
  • Collet J-P, Thiele H. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(20):2020–2021. doi: 10.1093/eurheartj/ehaa909.
  • Van Assche L, Peeters B, Vorlat A, et al. Safety and effectiveness of the short (0-1h) high sensitive troponin protocol in real-life practice. Acta Cardiol. 2023;78(8):937–944. doi: 10.1080/00015385.2023.2218028.
  • Vandebosch C, Dupont M, Verhaert D, et al. Severe coronary artery spasm after administration of a 5-hydroxytryptamine type 1 receptor agonist in a patient with new-onset graves’ disease and myocarditis after SARS-CoV2-vaccination. Acta Cardiol. 2023;78(8):889–893. doi: 10.1080/00015385.2022.2135224.
  • Kleebayoon A, Wiwanitkit V. Severe coronary artery spasm after administration of a 5-hydroxytryptamine type 1 receptor agonist and SARS-CoV2 vaccination. Acta Cardiol. 2023;78(8):974. doi: 10.1080/00015385.2023.2169438.
  • Özveren O, Tanalp AC, Tanboğa İH, et al. A new marker for the prediction of contrast induced-acute kidney injury following primary percutaneous coronary intervention: hemoglobin-albumin product. Acta Cardiol. 2023;78(8):901–909. doi: 10.1080/00015385.2023.2187126.
  • Yildiz C, Yuksel Y, Efe SC, et al. Value of systemic inflammation-response index in predicting contrast-induced nephropathy in patients with ST elevation myocardial infarction. Acta Cardiol. 2023;78(8):930–936. doi: 10.1080/00015385.2023.2218020.
  • Ma X, Mo C, Li Y, et al. Prediction of the development of contrast-induced nephropathy following percutaneous coronary artery intervention by machine learning. Acta Cardiol. 2023;78(8):912–921. doi: 10.1080/00015385.2023.2198937.
  • Del Rio-Pertuz G, Leelaviwat N, Mekraksakit P, et al. Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Acta Cardiol. 2023;78(8):922–929. doi: 10.1080/00015385.2023.2209406.
  • Choe JC, Oh J-H, Lee HC, et al. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial. Acta Cardiol. 2023;78(8):880–888. doi: 10.1080/00015385.2022.2129592.
  • Gitmez M, Lancellotti P. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomized trial. Acta Cardiol. 2023;78(8):975–976. doi: 10.1080/00015385.2023.2209441.
  • Jain A, Desai R, Shenwai P, et al. Impact of D-dimer levels on no-reflow phenomenon following percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. Acta Cardiol. 2023;78(8):970–973. doi: 10.1080/00015385.2022.2097346.
  • Carolino D'Araujo S, El-Mourad M. Coronary artery compression by left ventricular pseudoaneurysm – clinical case report. Acta Cardiol. 2023;78(8):959–961. doi: 10.1080/00015385.2022.2161741.
  • Wielgus K, Suchodolski A, Strojek M, et al. Single coronary artery with retrosternal course. Acta Cardiol. 2023;78(8):962–963. doi: 10.1080/00015385.2023.2229605.
  • Sonsöz MR, Şişman A, Güler A. What lies behind the extensive ST–segment changes in cardiac arrest? Acta Cardiol. 2023;78(8):966–967. doi: 10.1080/00015385.2023.2243062.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.